April 12, 2021 -- Twist Bioscience plans to exercise its option to purchase all rights to a G-coupled protein receptor (GPCR) library and its Twist antibody optimization software, both of which it developed in collaboration with Distributed Bio.
The library and the software were originally built as part of a 2016 license agreement between Twist Bioscience and Distributed Bio, according to the firm. Twist has been using the GPCR library and software together with its silicon-based DNA synthesis platform for the past two years to enable synthetic DNA writing oligo pool technology.
Building on the GPCR library, Twist Biopharma, a division of Twist Bioscience, generated a wide range of precision antibody discovery libraries, which now are encompassed in what the firm calls its "library of libraries," containing antibody fragment scaffolds as well as different sources of fully human antibody sequences.
Once binding antibodies are identified from the library of libraries or other sources, Twist Biopharma utilizes the Twist antibody optimization software and its custom library capacity to further optimize leads for improved pharmacokinetic, pharmacodynamic, binding, and other properties.
Financial terms of the agreement were not disclosed.